View More View Less
  • 1 Semmelweis University, Budapest, Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Sulfamethoxazole-trimethoprim (SXT) is the drug-of-choice in Stenotrophomonas maltophilia caused infections. There has been an increase in resistance to SXT of S. maltophilia over recent years. In this study 30 S. maltophilia clinical isolates resistant to SXT were investigated. Antibiotic susceptibilities for ciprofloxacin, moxifloxacin, levofloxacin, doxycycline, tigecycline, ceftazidime, colistin and chloramphenicol were determined by broth microdilution method. None of the strains were susceptible to ciprofloxacin, tigecycline, ceftazidime or colistin. Only 37% of the isolates were susceptible to levofloxacin or moxifloxacin. Two isolates resistant to all tested antibiotic agents and two others susceptible only to doxycycline were further investigated: susceptibility for combinations of antibiotics was analyzed by checkerboard technique. According to the fractional inhibitory concentration indices calculated, moxifloxacin plus ceftazidime combination was found to be synergistic in each case. Genetic testing revealed the predominance of sul1 gene. Our study concluded that the range of effective antibiotic agents is even more limited in infections caused by SXT-resistant S. maltophilia. In these cases, in vitro synergistic antibiotic combinations could be potential therapeutic options.

  • 1.

    Abbott, I. J., Slavin, M. A., Turnidge, J. D., Thursky, K. A., Worth, L. J.: Stenotrophomonas maltophilia: Emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 9(4), 471488 (2011).

    • Search Google Scholar
    • Export Citation
  • 2.

    Brooke, J. S.: Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev 25(1), 241 (2012).

  • 4.

    Looney, W. J., Narita, M., Mühlemann, K.: Stenotrophomonas maltophilia: An emerging opportunist human pathogen. Lancet Infect Dis 9(5), 312323 (2009).

    • Search Google Scholar
    • Export Citation
  • 5.

    Barbolla, R., Catalano, M., Orman, B. E., Famiglietti, A., Vay, C., Smayevsky, J., Centrón, D., Piñeiro, S. A.: Class 1 integrons increase trimethoprim–sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 48(2), 666669 (2004).

    • Search Google Scholar
    • Export Citation
  • 6.

    Chang, L. L., Lin, H. H., Chang, C. Y., Lu, P. L.: Increased incidence of class 1 integrons in trimethoprim/sulfamethoxazole–resistant clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 59(5), 10381039 (2007).

    • Search Google Scholar
    • Export Citation
  • 7.

    Hu, L. F., Chang, X., Ye, Y., Wang, Z. X., Shao, Y. B., Shi, W., Li, X., Li, J. B.: Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 37(3), 230234 (2011).

    • Search Google Scholar
    • Export Citation
  • 8.

    Hu, L. F., Gao, L. P., Ye, Y., Chen, X., Zhou, X. T., Yang, H. F., Liiu, Y. Y., Mei, Q., Li, J. B.: Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations. J Chemother 26(5), 282286 (2014).

    • Search Google Scholar
    • Export Citation
  • 9.

    Brooke, J. S.: New strategies against Stenotrophomonas maltophilia: A serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 12(1), 14 (2014).

    • Search Google Scholar
    • Export Citation
  • 10.

    San Gabriel, P., Zhou, J., Tabibi, S., Chen, Y., Trauzzi, M., Saiman, L.: Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48(1), 168171 (2004).

    • Search Google Scholar
    • Export Citation
  • 11.

    Milne, K. E., Gould, I. M.: Combination antimicrobial susceptibility testing of multidrug- resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother 56(8), 40714077 (2012).

    • Search Google Scholar
    • Export Citation
  • 12.

    Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing. CLSI approved Standard. M100 S16. CLSI, Wayne, PA, USA, 2012.

    • Search Google Scholar
    • Export Citation
  • 13.

    Balke, B., Hogardt, M., Schmoldt, S., Hoy, L., Weissbrodt, H., Häussler, S.: Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 25(1), 2530 (2006).

    • Search Google Scholar
    • Export Citation
  • 14.

    Betts, J. W., Phee, L. M., Woodford, N., Wareham, D. W.: Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 33(9), 15651572 (2014).

    • Search Google Scholar
    • Export Citation
  • 15.

    Garcia, L. S.: Clinical Microbiology Procedures Handbook. 3rd Edition, ASM Press, Washington DC, 2010, Chapter 5.12.

  • 16.

    Silbert, S., Pfaller, M. A., Hollis, R. J., Barth, A. L., Sader, H. S.: Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol 25(10), 847851 (2004).

    • Search Google Scholar
    • Export Citation
  • 17.

    Grape, M., Farra, A., Kronvall, G., Sundström, L.: Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. Clin Microbiol Infect 11(3), 185192 (2005).

    • Search Google Scholar
    • Export Citation
  • 18.

    Juhász, E., Krizsán, G., Lengyel, G., Grósz, G., Pongrácz, J., Kristóf, K.: Infection and colonization by Stenotrophomonas maltophilia: Antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob 13(1), 333 (2014).

    • Search Google Scholar
    • Export Citation
  • 19.

    Giamarellos-Bourboulis, E. J., Karnesis, L., Galani, I., Giamarellou, H.: In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 46(12), 39973999 (2002).

    • Search Google Scholar
    • Export Citation
  • 20.

    Wu, K., Yau, Y. C., Matukas, L., Waters, V.: Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 57(3), 15461548 (2013).

    • Search Google Scholar
    • Export Citation
  • 21.

    Giamarellos-Bourboulis, E. J., Karnesis, L., Giamarellou, H.: Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44(3), 259263 (2002).

    • Search Google Scholar
    • Export Citation
  • 22.

    Church, D., Lloyd, T., Peirano, G., Pitout, J.: Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis 45(4), 265270 (2013).

    • Search Google Scholar
    • Export Citation
  • 23.

    Visalli, M. A., Jacobs, M. R., Appelbaum, P. C.: Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 42(8), 20022005 (1998).

    • Search Google Scholar
    • Export Citation
  • 24.

    Entenza, J. M., Moreillon, P.: Tigecycline in combination with other antimicrobials: A review of in vitro, animal and case report studies. Int J Antimicrob Agents 34(1), 8.e19 (2009).

    • Search Google Scholar
    • Export Citation
  • 25.

    Gülmez, D., Cakar, A., Sener, B., Karakaya, J., Hasçelik, G.: Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 16(5), 322328 (2010).

    • Search Google Scholar
    • Export Citation
  • 26.

    Wood, G. C., Underwood, E. L., Croce, M. A., Swanson, J. M., Fabian, T. C.: Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmacother 44(10), 16651668 (2010).

    • Search Google Scholar
    • Export Citation
  • 27.

    Doern, C. D.: When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol 52(12), 41244128 (2014).

  • 28.

    Toleman, M. A., Bennett, P. M., Bennett, D. M., Jones, R. N., Walsh, T. R.: Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13(4), 559565 (2007).

    • Search Google Scholar
    • Export Citation

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
sumbission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 17 0 0
May 2021 11 0 0
Jun 2021 5 0 0
Jul 2021 5 0 0
Aug 2021 18 1 1
Sep 2021 27 0 0
Oct 2021 0 0 0